Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis
Recruiting
Phase 3
Interventional Study
Beta Blocker Toxicity
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* • Male \& female osteoporotic patient aged ≥ 50 years
* Hypertensive \& normotensive patients
* BMD T-score ≥ 2.5 or more SD below peak bone mass
Exclusion Criteria:
* Patients on drugs that may improve osteoporosis disease state such as:
* Angiotensin converting enz…
Contacts